Patients must have had prior treatment with anti-PD or anti-PD-L agents and had documented disease progression either while on these agents or after stopping therapy with these agents without intervening therapy; patients must have discontinued anti-PD- or anti-PD-L therapy at least  days prior to registration
Patients must not have had systemic therapy, excluding anti-PD- or anti-PD-L agents, within  days prior to registration
Prior treatment with lenvatinib or any PD-, anti-PD-L, or anti-PD-L agent, excluding melanoma and NSCLC where prior treatment with one PD-, anti-PD-L, or anti-PD-L agent is allowed
No prior therapy with a CDK / inhibitor; prior anti-PD- and anti-PD-L therapy is permitted
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Subject has already received one of the following therapy/treatment: anti-PD-, anti-PD-L, or anti-PD-L inhibitor.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L, or HSP inhibitor
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent; has been on any prior Merck MK- (pembrolizumab) studies
Refractory to prior anti-PD-/PD-L agent
The subject has received prior pembrolizumab or any other anti-PD-, anti-PD-L, or anti-PD-L therapy, or has participated in any prior studies involving pembrolizumab
Prior treatment with lenvatinib or any anti-PD-, anti-PD-L, or anti-PD-L agent
Intolerance to prior anti-PD-/PD-L therapy
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent; please contact the principal investigator for further clarification if needed
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
COHORT : Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
COHORT : Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior exposure to an anti-PD-, anti-PD-L or anti-PD-L
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent (only cohort A)
Prior therapy with a PD-, anti-PD-Ligand  (PD-L), or anti-PD-L agent, or previously participated in Merck pembrolizumab (MK-) study
Previous treatment with any anti-PD-, PD-L, or PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or with an agent directed to another co-inhibitory T-cell receptor.
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Patients who have received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent are not eligible
Prior disease progression on anti-PD- therapy
Previous treatment with any anti-PD-, PD-L, or PD-L agent
Received prior therapy with an anti-CTLA-, anti-PD-, anti-PD-ligand- (anti-PD-L), or anti-PD- ligand- (anti-PD-L) agent within  weeks prior to initiation of study treatment depending on study part
Prior treatment with anti-PD- or PD-L therapies
The participant has received prior pembrolizumab or any other anti-PD-, anti-PD-L, or anti-PD-L therapy, or has participated in any prior studies involving pembrolizumab
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent\r\n* This criterion does not apply to eligibility for second course treatment
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Prior immunotherapy including anti-PD-, anti-PD-L, or anti-PD-L agents
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-, OX-, CD)
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
For Parts B and C, patients who received previous anti- PD-, anti-PD-(L) treatment
Patients may not have received prior anti PD- or anti PD-L inhibitors
History of prior therapy with an IDO inhibitor in combination with an anti-PD-/anti-PD-L agent/any other drug specifically targeting checkpoint pathways; patients who have received prior therapy with single agent anti-PD-/anti-PD-L therapy or single agent IDO inhibitor will be eligible for this study
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR) (e.g., CTLA-, OX , CD).
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior treatment with anti-PD or anti-PD-L antibody therapy
Has received prior therapy with an anti-PD-, anti-PD-L, anti-CTLA or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Prior therapy with an anti-PD-, anti-PD-L, anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Previous anti-PD or anti-PD-L
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent within the prior  weeks
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L, anti-CTLA- agent, or mifepristone
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has been receiving anti-PD- or anti-PD-L immunotherapy for at least four weeks
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Patients who received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent without having had evidence of objective response
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior immunotherapy or treatment with another anti PD  agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Previous therapy for this cancer with an anti-PD-, anti-PD-L, anti-PD-L agent, or any other immunomodulatory agent
Has received prior anti-PD- or anti-PD-L therapy
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior immunotherapy including anti-PD-, anti-PD-L, or anti-PD-L agents, or if the subject has previously participated in Merck pembrolizumab clinical trials
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Anti-PD-, anti-PD-L, or anti-PD-L agents
Has received prior therapy with an anti-PD-, anti-PD-L-, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent, or sEsphB-HSA
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has had prior treatment with any other anti-PD- or PD-L or PD-L agent
Prior treatment with an anti-PD-, anti-PD-L or anti-PD-L agent
Prior treatment with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent.
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L
Patient had prior treatment with any other anti-PD-, or PD-ligand (L) or PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Patients who discontinued prior anti-PD-/PD-L therapy due to an anti-PD-/PD-L-related toxicity.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or blinatumomab
REGISTRATION TO TREATMENT (STEP ): Patient must not have received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent for dose expansion; (patients in dose escalation may have received an anti-PD-, anti-PD-L, or anti-PD-L agent)
Prior therapy with anti-PD-, PD-L, or PD-L agent.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent, or other immune checkpoint inhibitor (e.g. anti-CTLA)
Patients may not have had any prior ipilimumab and/or anti-PD-/PD-L agent in the metastatic setting
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-, OX-, CD)
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L antibody.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or if the patient has previously participated in MK- clinical trials.
Has received prior therapy with an anti-PD-, or anti-PD-L, or anti-PD-L agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein  [CTLA-], OX-, CD).
Prior treatment with an anti-PD-, anti-PD-L, or anti-PD-L agent
No prior treatment with anti-PD- or anti-PD-L
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or if the patient has previously participated in Merck MK- clinical trials.
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or if the subject has previously participated in Merck MK- clinical trials.
Anti PD-/PD-L relapsed cohorts (I and II), participants whose most recent anti-cancer therapy consisted of single-agent PD-/PD-L blockade will be enrolled
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or if the patient has previously participated in a Merck MK- clinical trial.
Intolerance to prior anti-PD-/PD-L therapy
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or has participated in another Merck pembrolizumab clinical trial
Prior therapy with a PD-, anti-PD-Ligand  (PD-L), or anti-PD-L agent, or previously participated in a Merck pembrolizumab (MK-) study
Has received prior therapy with an anti-PD-, anti-PD-L, anti-PD-L, OR other immune check point agonist/inhibitor.
Prior treatment with an anti-PD-, anti-PD-L, anti-PD-L monoclonal antibody.
Prior immunotherapy including anti-PD-, anti-PD-L, or anti-PD-L agent, or previously participated in Merck pembrolizumab (MK-) clinical trial
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent or previously participated in Merck MK- clinical trial
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent, or with an agent directed to another co-inhibitory T-cell receptor
Prior therapy with an anti-PD- or anti-PD-L or -L therapy or previously participated in a Merck pembrolizumab (MK-) trial
Histological or cytological diagnosis of NSCLC. Patients must have ) previously received prior anti-PD-L or anti-PD- mAb as most recent therapy, AND ) did not have progressive disease as best overall response on recent PD-L/PD- therapy (ie, stable disease  months, PR, or CR), AND ) who subsequently progressed on anti-PD-L or anti-PD- mAb.
Patients who received prior anti-PD- therapy are eligible for cohort  only and patients who have not received prior anti-PD- therapy are eligible for cohort  only
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
With TNBC has received prior therapy with an anti-PD-, anti-PD-L, anti-CTLA-, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Previous treatment with anti-PD-, anti-PD-L or anti-PD-L therapy.
Prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior treatment with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L
Patient must have had prior treatment with anti-PD- or anti-PD-L agents and have documented disease progression on these agents prior to registration; patient must have received anti-PD- or PD-L based therapy as the immediate previous line of treatment and within  days prior to registration
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Prior treatment with anti PD- or PD-L therapy (Arm A)
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Subjects who are currently receiving treatment with the anti-PD- antibody Pembrolizumab either alone or in combination and are progressing. Subjects must have received at least  doses of anti-PD-/PD-L therapy OR
Subjects who have previously received any anti-PD-/PD-L therapy, alone or in combination. Subjects must have received at least  doses of anti-PD-/PD-L therapy
Received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent
Has received prior therapy with an anti-PD-, anti-PD-L, or anti-PD-L agent